Obrosova et al., 2001 - Google Patents

Antioxidants attenuate early up regulation of retinal vascular endothelial growth factor in streptozotocin-diabetic rats

Obrosova et al., 2001

View PDF

Document ID: 11753935712415941370
Author: Obrosova I; Minchenko A; Marinescu V; Fathallah L; Kennedy A; Stockert C; Frank R; Stevens M
Publication year: 2001
Publication venue: Diabetologia

External Links

Cited by

Snippet

Aims/hypothesis: A strong positive correlation has been found between lipid peroxidation product and vascular endothelial growth factor concentrations in the vitreous of patients with proliferative diabetic retinopathy. To establish a causal relation between diabetes …

Continue reading at link.springer.com (PDF) (other versions)

108010073929 Vascular Endothelial Growth Factor A 0 title abstract description 94

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K8/00—Cosmetic or similar toilet preparations
- A61K8/18—Cosmetic or similar toilet preparations characterised by the composition
- A61K8/30—Cosmetic or similar toilet preparations characterised by the composition containing organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (-N=N-), diazo (=N2), azoxy (>N-O-N< or N(=O)-N<), azido (-N3) or diazoamino (-N=N-N<) compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists

Similar Documents

Publication	Publication Date	Title
Obrosova et al.	2001	Antioxidants attenuate early up regulation of retinal vascular endothelial growth factor in streptozotocin-diabetic rats
Craven et al.	1997	Effects of supplementation with vitamin C or E on albuminuria, glomerular TGF-beta, and glomerular size in diabetes.
US7671086B2 (en)	2010-03-02	Pharmaceutical compositions comprising flavonoids and menthol
Kowluru	2001	Diabetes-induced elevations in retinal oxidative stress, protein kinase C and nitric oxide are interrelated
Al-Dalain et al.	2001	Ozone treatment reduces markers of oxidative and endothelial damage in an experimental diabetes model in rats
Lal et al.	2002	Role of oxidative stress in advanced glycation end product-induced mesangial cell activation
US20080139664A1 (en)	2008-06-12	Anti-glycation agents for preventing age-, diabetes-, and smoking-related complications
Mukerji et al.	1984	Dual mechanism of inhibition of rat liver uroporphyrinogen decarboxylase activity by ferrous iron: its potential role in the genesis of porphyria cutanea tarda
Obrosova et al.	2000	Evaluation of α1‐adrenoceptor antagonist on diabetes‐induced changes in peripheral nerve function, metabolism, and antioxidative defense
Li et al.	2020	Mangiferin exerts neuroprotective activity against lead-induced toxicity and oxidative stress via Nrf2 pathway
Weber et al.	1990	Depletion of tissue glutathione with diethyl maleate enhances hyperbaric oxygen toxicity
Liu et al.	2009	Aldo-keto reductase family 1 member B1 inhibitors: old drugs with new perspectives
Adegbesan et al.	2021	ORAL CELLGEVITY® improves antioxidant parameters and stalls damages in STZ-diabetic rat pancreas
Herrera et al.	2001	Glutamate induces oxidative stress not mediated by glutamate receptors or cystine transporters: protective effect of melatonin and other antioxidants
Salahudeen et al.	1998	Cisplatin induces N-acetyl cysteine suppressible F2-isoprostane production and injury in renal tubular epithelial cells.
Djukic et al.	2007	The role of nitric oxide in paraquat-induced oxidative stress in rat striatum
Frank et al.	2001	Antioxidants attenuate early up regulation of retinal vascular endothelial growth factor in streptozotocin-diabetic rats
Babizhayev	2010	New concept in nutrition for the maintenance of the aging eye redox regulation and therapeutic treatment of cataract disease; synergism of natural antioxidant imidazole-containing amino acid-based compounds, chaperone, and glutathione boosting agents: a systemic perspective on aging and longevity emerged from studies in humans
Jenkinson et al.	1988	BCNU-induced protection from hyperbaric hyperoxia: role of glutathione metabolism
Mendez et al.	1996	Oxidants augment endotoxin-induced activation of alveolar macrophages
Penttilä et al.	1987	Allyl alcohol liver injury: suppression by ethanol and relation to transient glutathione depletion
Nishida et al.	1998	Teprenone, an anti-ulcer agent, increases gastric mucosal mucus level via nitric oxide in rats
Nair et al.	2023	Aldose reductase and protein glycation inhibitory activity of dark chocolate-assisted zinc oxide nanoparticles
Sandhir et al.	2006	Influence of ethanol on methanol‐induced oxidative stress and neurobehavioral deficits
Woollard et al.	1990	Abnormal redox status without increased lipid peroxidation in sugar cataract